reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
AVAV AEROVIRONMENT INC.
KFS KINGSWAY FINANCIAL SERVICES
PAYS PAYSIGN INC
PRCH PORCH GROUP INC (A)
SPNT SIRIUSPOINT LTD
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
OSCR OSCAR HEALTH
JOBY JOBY AVIATION INC
COIN COINBASE GLOBAL INC
EVEX EVE HOLDING INC
GCT GIGACLOUD TECHNOLOGY INC
CRBG COREBRIDGE FINANCIAL INC.
SGHC SUPER GROUP (SGHC) LIMITED
RDW REDWIRE CORP
DAVE DAVE INC
GRALV GRAIL INC.
SMCI SUPER MICRO COMPUTER INC.
EVTL VERTICAL AEROSPACE LTD.
ANET ARISTA NETWORKS INC
OWLT OWLET INC
ESP BROMPTON ENERGY SPLIT CORP
Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Result...
Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted PMA supplement for second-generation LungFit® PH to FDA International distribution partnerships now provide access to markets representing over 2 billion lives, with LungFit® PH actively shipping to Europe,...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
OXY OCCIDENTAL PETROLEUM CORPORATION
VSAT VIASAT INC.
RDWR RADWARE LTD.
MRCY MERCURY SYSTEMS INC.
GTE GRAN TIERRA ENERGY
DAR DARLING INGREDIENTS INC.
AVAV AEROVIRONMENT INC.
EFR ENERGY FUELS
NEM NEMETSCHEK SE
FSLR FIRST SOLAR INC.
SJT SAN JUAN BASIN ROYALTY TRUST
LEU CENTRUS ENERGY CORPORATION
ISSC INNOVATIVE SOLUTIONS & SUPPORT INC.
SDRL SEADRILL LTD.
NEON NEONODE INC.
LHX L3HARRIS TECHNOLOGIES INC
JAN JANONE INC
MP MP MATERIALS CORP (A)
RTX RAYTHEON TECHNOLOGIES CORPORATION
APA APA CORPORATION
SHLS SHOALS TECHNOLOGIES GROUP
OVV OVINTIV INC
SBTX SILVERBACK THERAPEUTICS
CIVI CIVITAS RESOURCES INC
ASTS AST SPACEMOBILE INC
CHRD CHORD ENERGY CORPORATION
METC RAMACO RESOURCES INC.
UMAC UNUSUAL MACHS INC NEV
VG VENTURE GLOBAL INC.
OWLT OWLET INC
Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH
Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH LungFit PH II’s smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the country GARDEN CITY, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the submission of a premarket app...
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference...
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 on Tuesday, June 17, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm E...
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections U...
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a p...
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndr...
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating ASD in 2026 BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for autism and Alzheimer disorders, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug ...
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Sc...
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer’s Disease BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and Alzheimer’s disease (AD)conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Nobel Prize laureate, Professor Dan...
Beyond Air Publishes Article in Annals of the American Thoracic Societ...
Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the publication of its scientific article, “A Pilot Study to Assess the Effect of Intermittent In...
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demo...
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a subsidiary of Beyond Air (NASDAQ: XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, ...
Beyond Air Announces Vanderbilt University Medical Center as First Lum...
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology GARDEN CITY, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Vanderbilt Unive...
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an ...
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, includin...
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
OPK OPKO HEALTH INC.
FRPT FRESHPET INC
HRTG HERITAGE INSURANCE HOLDINGS INC.
CULP CULP INC.
MAC MACERICH COMPANY
ORN ORION GROUP HOLDINGS
TREE LENDINGTREE INC.
NKSH NATIONAL BANKSHARES INC.
FLWS 1-800-FLOWERS.COM CL A
MX MAGNACHIP SEMICONDUCTOR CORP.
TCPC BLACKROCK TCP CAPITAL CORP.
XAIR BEYOND AIR
CMPR CIMPRESS PLC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
PRDO PERDOCEO EDUCATION CORP
FET FORUM ENERGY TECHNOLOGIES
SEAT VIVID SEATS INC.
FLNC FLUENCE ENERGY INC
BTMD HAYMAKER ACQUISITION CORP III
ECAT BLACKROCK ESG CAP ALLOCATION TR
ONL ORION OFFICE REIT INC
MLYS MINERALYS THERAPEUTICS INC
DK DELEK US HOLDINGS
CVI INC.
CUBA CVR ENERGY
SUNS INC.
AFCG THE HERZFELD CARIBBEAN BASIN FUND
INC.
SUNRISE REALTY TRUST
AFC GAMMA
INC.
AV’s Cutting-Edge One-Way Attack UAS Secures DIU Backing Under Project...
ARLINGTON, Va.--(BUSINESS WIRE)-- AeroVironment (AV), the leader in defense technology, has secured a contract with the Defense Innovation Unit (DIU) to accelerate the deployment of next-generation autonomous precision munitions. As part of its strategic expansion into a new sector of the multi-billion-dollar defense market, AV has been awarded an Other Transaction Authority (OT) award by the Defense Innovation Unit (DIU) as part of Project Artemis, an initiative launched to rapidly test and operationally evaluate long-range, one-way uncrewed aircraft systems (UAS) for the Department of Defen...
Beyond Air Announces Agreements Expanding Global Distribution of LungF...
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, ann...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferen...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual Growth Stock Conference being held March 16-18, 2025 in Laguna, CA and the Jones Healthcare and Technology Innovation Confere...
AeroVironment Announces Fiscal 2025 Third Quarter Results
ARLINGTON, Va.--(BUSINESS WIRE)-- (“AeroVironment” or the “Company”) reported today financial results for the fiscal third quarter ended January 25, 2025. Third Quarter Highlights: Record funded backlog of $763.5 million as of January 25, 2025 Third quarter revenue of $167.6 million down 10% year-over-year Third quarter net loss of $(1.8) million and non-GAAP adjusted EBITDA of $21.8 million “We faced a number of short-term challenges in the third quarter, including the unprecedented high winds and fires in Southern California, which impacted our ability to meet our goals,” said Wahi...
AeroVironment, Inc. to Announce Third Quarter Fiscal Year 2025 Earning...
ARLINGTON, Va.--(BUSINESS WIRE)-- (NASDAQ: AVAV) will report its financial results for the third quarter of fiscal year 2025, which ended January 25, 2025, after the market closes on Wednesday, March 4, 2025. Management will host a conference call and live audio webcast at 4:30 p.m. Eastern Time that same day to discuss the results. The call will be led by Wahid Nawabi, AeroVironment’s chairman, president, and chief executive officer; Kevin P. McDonnell, senior vice president and chief financial officer; and Jonah Teeter-Balin, vice president of corporate development and investor relations. ...
AV Unveils JUMP 20-X: Revolutionizing Autonomous Maritime Operations w...
ABU DHABI, United Arab Emirates--(BUSINESS WIRE)-- AeroVironment (AV), a global leader in intelligent, multi-domain autonomous solutions, today announced the launch of the JUMP® 20-X, a next-generation, modular Group 3 uncrewed aircraft system (UAS) designed to meet the dynamic demands of modern warfare. Setting a new benchmark for autonomous maritime operations, the JUMP 20-X delivers unrivaled versatility, efficiency, and precision in contested and complex environments. This press release features multimedia. View the full release here: JUMP 20-X executes a precision landing on a rapidly mo...
AV Expands U.S. Manufacturing in Salt Lake City, Utah with FreedomWerx...
ARLINGTON, Va.--(BUSINESS WIRE)-- AeroVironment (AV), the leader in autonomous and intelligent multi-domain systems, today announced the establishment of FreedomWerx, a state-of-the-art advanced manufacturing facility in Salt Lake City, Utah. This press release features multimedia. View the full release here: New 200,000-square-foot facility will expand production of AV’s battle-proven Loitering Munitions Systems (Photo: AV) As part of AV’s distributed production strategy, FreedomWerx strengthens the company’s capacity to ensure uninterrupted delivery of precision-strike autonomous systems to...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.